- ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.Shen, Peng; Zeng, Di; Lin, Zhenzi; Lin, Pei; Luo, Mingyang; Zhao, Lele; Chai, Huizi; Huang, Lingli; Xiao, MingzheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- PALB2 mutation as a predictive biomarker for immunotherapy in patients with advanced melanoma: Results from (a pooled analysis of) five multicenter, randomized clinical trials.You, Changxuan; Zheng, Yating; Huang, MengliVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.被引 1
- Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective studyWu, Shaowei; Zhou, HaiYu; Xie, Daipeng; Yao, LintongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced non-small cell lung cancer.
13阅读
